Genomic Psychiatry

Aims & Scope

Genomic Psychiatry: Advancing Science from Genes to Societystands as a leading journal advancing mental health science by connecting genetics and genomics with broader implications. Julio Licinio, MD, PhD, MBA, MS, is a renowned psychiatrist and an internationally recognized research leader in neuroscience, stress, pharmacogenomics, microbiome, and depression. He is the inaugural Editor-in-Chief (EIC) of Genomic Psychiatry. Dr. Licinio is a board-certified psychiatrist by the American Board of Psychiatry and Neurology, and he is a Fellow of the Royal Australian and New Zealand College of Psychiatrists (FRANZCP) and a Fellow of the Australian Academy of Health and Medical Sciences (FAAHMS). Dr. Licinio has published 327 research papers listed in Pubmed. His work has been cited 42,166 times, and his h-index is 90. In his career spanning over 30 years, Dr. Licinio has founded and led four journals from inception to full indexing and high impact. He has edited and published 44 articles by 9 Nobel Prize laureates in the last seven years alone, including 19 by the late Nobel laureate Paul Greengard. Dr. Licinio is a seasoned Editor-in-Chief, having raised the impact factor and rankings of the first journal he launched, which went from non-existent to number 1 worldwide in just 13 years. Our Editorial Board has eminent international experts. Confirmed members of the Editorial Board include: Kristen Brennand,Yale University School of Medicine, New Haven, Connecticut 06511, USA

A twelfth criterion — whether APC fees are clearly disclosed — is not scored here; it is left out of the total rather than counted as a failure. Publication charges appear in the metrics card above.

Based on the Think.Check.Submit framework by DOAJ, COPE & OASPA. All data from verified open sources.

Source: OpenAlex · Each year’s green bar = citations earned by that year’s papers, counted to date — so recent years look lower simply because their papers haven’t had time to be cited yet.

Subject Classification